Klotho Neurosciences Stock Surges 175% on Lifespan Extension Breakthrough
Klotho Neurosciences (KLTO) shares skyrocketed in pre-market trading after unveiling groundbreaking preclinical data. The biopharmaceutical firm's research suggests genetic overexpression of the α-KLOTHO gene could extend mammalian lifespan by 30-40%, based on murine studies.
The company secured exclusive worldwide rights to s-KL, a potential therapy targeting neurodegenerative and age-related conditions. This dual catalyst propelled KLTO stock to a 175.61% gain, though the equity remains down 96% year-over-year.